This website uses cookies to enhance the user experience.
C

CEROLU AS998 290 163

Research
Limited company
Svaleveien 5A 1182 OSLO, Norge

CEROLU AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
13 years
since May 10, 2012
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
30,000
1 share class
Total number of shareholders
1
person

Financials

Annual total result 2024
-1,143,070
NOK
Total equity 2024
-396,176
NOK
Last update: May 22, 2025

Management

Board

NameRoleShares
Contact Person, Chairman-
Alternate Member-

Others

NameRoleShares
K
KR ØKONOMI AS
Accountant-
Last update: Apr 13, 2023

Ownership

Company shareholders

NameShare classTotal number of sharesShare
Ordinary shares
30,000
100 %

Shares owned by the CEROLU AS

NameShare classTotal number of sharesShare
B
BIOMOLEX AS
NO0010162266
94,000
11.3 %
A
ARCTIC PHARMA AS
Ordinary shares
3,279
3 %
V
VITAE EVIDENCE AS
Ordinary shares
767
1.04 %
C
COREMINE VITAE AS
Ordinary shares
1,391
0.09 %
Last update: Jun 2, 2025

Financials

in NOK

Summary

Year2024202320222021
Total operating income
0
363,000
403,700
493,900
Annual Total Result
-1,143,070
23,240
33,916
111,496
Total assets
29,452
1,194,779
1,126,238
1,110,844
Total liabilities
425,628
447,885
402,585
421,107
Total equity
-396,176
746,894
723,654
689,738

P&L

Year2024202320222021
Total operating income
0
363,000
403,700
493,900
Total operating costs
127,546
324,237
355,311
350,303
Operating result
-127,546
38,763
48,389
143,597
Financial income/costs
-1,015,524
-9,034
-4,894
-655
Profit before tax
-1,143,070
29,729
43,495
142,943
Total tax & extraordinary income/cost
0
6,489
9,579
31,447
Annual Total Result
-1,143,070
23,240
33,916
111,496

Balance overview

Year2024202320222021
Total fixed assets
0
959,109
949,815
919,815
Total current assets
29,452
235,670
176,424
191,029
Total assets
29,452
1,194,779
1,126,238
1,110,844
Short term debt
425,628
447,885
402,585
421,107
Long term debt
0
0
0
0
Total liabilities
425,628
447,885
402,585
421,107
Contributed capital
30,000
30,000
30,000
30,000
Retained earnings
-426,176
716,894
693,654
659,738
Total equity
-396,176
746,894
723,654
689,738
Total equity and liabilities
29,452
1,194,779
1,126,238
1,110,844

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology